These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30488021)

  • 41. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
    Sangro B
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
    Kim YW; Kwon JH; Nam SW; Jang JW; Jung HS; Shin YR; Park ES; Shim DJ
    Exp Ther Med; 2018 Feb; 15(2):1479-1483. PubMed ID: 29434732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion.
    Nishi M; Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    Hepatol Res; 2018 Mar; 48(4):329-332. PubMed ID: 29098752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
    Recchia F; Passalacqua G; Filauri P; Doddi M; Boscarato P; Candeloro G; Necozione S; Desideri G; Rea S
    Oncol Rep; 2012 May; 27(5):1377-83. PubMed ID: 22294036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis.
    Zeng JY; Piao XH; Zou ZY; Yang QF; Qin ZL; Chen JB; Zhou L; Niu LZ; Liu JG
    Oncotarget; 2018 Jan; 9(7):7557-7566. PubMed ID: 29484132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.
    Cheng AL; Amarapurkar D; Chao Y; Chen PJ; Geschwind JF; Goh KL; Han KH; Kudo M; Lee HC; Lee RC; Lesmana LA; Lim HY; Paik SW; Poon RT; Tan CK; Tanwandee T; Teng G; Park JW
    Liver Int; 2014 Feb; 34(2):174-83. PubMed ID: 24251922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of diffuse hepatocellular carcinoma (≧ 10 Lesions) with doxorubicin-loaded DC beads is a safe and effective treatment option.
    Cannon RM; Urbano J; Kralj I; Bosnjakovic P; Martin RC
    Onkologie; 2012; 35(4):184-8. PubMed ID: 22488088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).
    Lu J; Zhao M; Arai Y; Zhong BY; Zhu HD; Qi XL; de Baere T; Pua U; Yoon HK; Madoff DC; Teng GJ;
    Hepatobiliary Surg Nutr; 2021 Oct; 10(5):661-671. PubMed ID: 34760969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma.
    van Malenstein H; Maleux G; Vandecaveye V; Heye S; Laleman W; van Pelt J; Vaninbroukx J; Nevens F; Verslype C
    Onkologie; 2011; 34(7):368-76. PubMed ID: 21734423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].
    Malbranche C; Boulin M; Guiu B; Pernot C; Cercueil JP; Serge Aho L; Musat A; Bedenne L; Hillon P; Guignard MH; Fagnoni P
    Bull Cancer; 2011 Jun; 98(6):671-8. PubMed ID: 21642049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
    Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma.
    Galastri FL; Nasser F; Affonso BB; Valle LGM; Odísio BC; Motta-Leal Filho JM; Salvalaggio PR; Garcia RG; de Almeida MD; Baroni RH; Wolosker N
    World J Hepatol; 2020 Jan; 12(1):21-33. PubMed ID: 31984118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-Eluting Bead Transarterial Chemoembolization as Bridge Therapy for Hepatocellular Carcinoma Before Living-Donor Liver Transplantation.
    Yu CY; Ou HY; Weng CC; Huang TL; Chen TY; Leung-Chit L; Hsu HW; Chen CL; Cheng YF
    Transplant Proc; 2016 May; 48(4):1045-8. PubMed ID: 27320552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Shiozawa K; Watanabe M; Ikehara T; Ogino Y; Umakoshi T; Matsukiyo Y; Kogame M; Matsui T; Kikuchi Y; Igarashi Y; Sumino Y
    Case Rep Oncol; 2014 Sep; 7(3):739-45. PubMed ID: 25520649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
    Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioembolization Versus Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study.
    Akinwande O; Philips P; Scoggins C; Martin RC
    Anticancer Res; 2016 Jan; 36(1):239-46. PubMed ID: 26722049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes.
    Rostas J; Tam A; Sato T; Kelly L; Tatum C; Scoggins C; McMasters K; Martin RCG
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1392-1400. PubMed ID: 28508253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.